Skip to main content

DOI: 10.3390/biom13091283

Submitted by JessicaWheeler on
NPRC/Institute
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, China
Summary of Study
IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Combined with Neutralizing Antibodies
Year Published
2023
References
DOI: 10.3390/biom13091283
Contact Info
Shibo Jiang:shibojiang@fudan.edu.cn; Shuai Xia: sxia15@fudan.edu.cn
Keywords
SARS-CoV-2, fusion inhibitor, IgG-binding peptide, immune response, primates
Coronavirus Investigated*
NHP Species
date entered